Cadrenal Therapeutics
$1.2800
23
-$0.05-3.76% Thursday 20:00
-$0.01-0.78%Thursday 23:59After hours
Statistics
Day High
1.3
Day Low
1.28
52W High
14.64
52W Low
1.27
Volume
199
Avg. Volume
-
Mkt Cap
4.57M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.15
-1.74
-1.33
-0.91
Expected EPS
-0.913333
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-13.24MNet Income
Analyst Ratings
13.00Average Price Target
The highest estimate is 13.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow CVKD. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap233.78B
Novartis
NVS
Mkt Cap292.35B
Pfizer
PFE
Mkt Cap159.36B
Merck
MRK
Mkt Cap366B
Bristol-Myers Squibb
BMY
Mkt Cap136B
Astrazeneca
AZN
Mkt Cap252.33B
Johnson & Johnson
JNJ
Mkt Cap645.95B
Gilead Sciences
GILD
Mkt Cap180.64B
Abbvie
ABBV
Mkt Cap451.46B
Sanofi
SNY
Mkt Cap107.39B
About
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Show more...
CEO
Quang X. Pham
Employees
5
Country
United States
ISIN
US1276362076
Listings
0 Comments
Share your thoughts
FAQ
What is Cadrenal Therapeutics stock price today?▼
The current price of CVKD is $1.28 USD — it has decreased by -3.76% in the past 24 hours. Watch Cadrenal Therapeutics stock price performance more closely on the chart.
What is Cadrenal Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cadrenal Therapeutics stocks are traded under the ticker CVKD.
Is Cadrenal Therapeutics stock price growing?▼
CVKD stock has fallen by -16.88% compared to the previous week, the month change is a -36.95% fall, over the last year Cadrenal Therapeutics has showed a -89.77% decrease.
What is Cadrenal Therapeutics market cap?▼
Today Cadrenal Therapeutics has the market capitalization of 4.57M
When is the next Cadrenal Therapeutics earnings date?▼
Cadrenal Therapeutics is going to release the next earnings report on November 05, 2026.
What were Cadrenal Therapeutics earnings last quarter?▼
CVKD earnings for the last quarter are -1.14 USD per share, whereas the estimation was -1.42 USD resulting in a +19.72% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cadrenal Therapeutics revenue for the last year?▼
Cadrenal Therapeutics revenue for the last year amounts to 0 USD.
What is Cadrenal Therapeutics net income for the last year?▼
CVKD net income for the last year is -13.24M USD.
How many employees does Cadrenal Therapeutics have?▼
As of September 04, 2026, the company has 5 employees.
In which sector is Cadrenal Therapeutics located?▼
Cadrenal Therapeutics operates in the Health & Wellness sector.
When did Cadrenal Therapeutics complete a stock split?▼
The last stock split for Cadrenal Therapeutics was on August 20, 2024 with a ratio of 1:15.
Where is Cadrenal Therapeutics headquartered?▼
Cadrenal Therapeutics is headquartered in PONTE VEDRA, United States.